Sugi Predict

Sugi Predict / Compounds / SCHEMBL2956515

SCHEMBL2956515

SCHEMBL2956515

CC(Sc1cccc(-c2nc(=O)c3ccccc3s2)n1)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MIF P14174 1/20 0.51
▸ GABRA1 P14867 1/20 0.51
▸ RAB9A P51151 6/20 0.35
▸ MAPT P10636 6/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ PAX8 Q06710 1/20 0.35
▸ NOD2 Q9HC29 1/20 0.35
▸ ALDH1A1 P00352 8/20 0.35
▸ CASP3 P42574 1/20 0.35
▸ SENP7 Q9BQF6 1/20 0.35
▸ SENP6 Q9GZR1 1/20 0.35
▸ NPSR1 Q6W5P4 7/20 0.34
▸ NPC1 O15118 5/20 0.34
▸ LMNA P02545 4/20 0.34
▸ SMN1; SMN2 Q16637 4/20 0.34
▸ TP53 P04637 2/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ KMT2A Q03164 5/20 0.34
▸ MEN1 O00255 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2956272 0.88 MIF (0.56) MIFGABRA1RAB9AMAPTL3MBTL1
SCHEMBL2963187 0.81 MIF (0.59) MIFGABRA1RAB9AMAPTALDH1A1
SCHEMBL2963007 0.81 MIF (0.56) MIFGABRA1RAB9AMAPTL3MBTL1
SCHEMBL2952904 0.78 MIF (0.50) MIFGABRA1RAB9AMAPTL3MBTL1
SCHEMBL13217133 0.78 MIF (0.56) MIFGABRA1RAB9AMAPTL3MBTL1
SCHEMBL2961631 0.78 MIF (0.56) MIFGABRA1RAB9AMAPTALDH1A1
SCHEMBL2955422 0.76 MIF (0.53) MIFGABRA1RAB9AMAPTALDH1A1
SCHEMBL2959169 0.76 MIF (0.53) MIFGABRA1RAB9AMAPTALDH1A1
SCHEMBL2953102 0.76 MIF (0.53) MIFGABRA1RAB9AMAPTALDH1A1
SCHEMBL2949342 0.75 MIF (0.52) MIFGABRA1RAB9AMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767665-B2 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-03 — — US disclosed
US-20090082343-A1 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-03-26 — — US disclosed
US-7399759-B2 1, 3-benzothiazinone derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-15 — — US disclosed
EP-1424336-A1 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2004-06-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082343-A1 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF MIF, MORF4L1, FOXM1 MIF 1/4885GABRA1 3323/4885RAB9A 4678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.